Market Research Logo

Global Cancer Monoclonal Antibodies Market 2017-2021

Global Cancer Monoclonal Antibodies Market 2017-2021

About Cancer Monoclonal Antibodies

The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.

Technavio’s analysts forecast the global cancer monoclonal antibodies market to grow at a CAGR of 10.86% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global cancer monoclonal antibodies market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded cancer mAbs and biosimilars used to treat cancer. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Cancer Monoclonal Antibodies Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hoffmann-La Roche
  • Amgen
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals
Other prominent vendors
  • AbbVie
  • ADC Therapeutics
  • Agensys
  • Argos Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • BioGenomics
  • Boehringer Ingelheim
  • Celldex Therapeutics
  • Chugai Pharmaceutical
  • CTI BioPharma
  • Daiichi Sankyo
  • Eli Lilly
  • Fortress Biotech
  • Genmab
  • Immunomedics
  • Intas Pharmaceuticals
  • Janssen Biotech
  • Kyowa Hakko Kirin
  • Merck
  • MedImmune
  • Morphotek
  • Neovii Biotech
  • Novartis
  • OncoMed Pharmaceuticals
  • Pfizer
  • Sanofi
  • Seattle Genetics
  • TG Therapeutics
  • Xbiotech
Market driver
  • Increase in demand for ADCs
  • For a full, detailed list, view our report
Market challenge
  • Complicated regulatory framework
  • For a full, detailed list, view our report
Market trend
  • Emergence of targeted and combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Cancer Monoclonal Antibodies Market 2017-2021

Technavio recognizes the following companies as the key players in the global cancer monoclonal antibodies market: F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, and Takeda Pharmaceuticals.

Other Prominent Vendors in the market are: AbbVie, ADC Therapeutics, Agensys, Argos Therapeutics, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, BioGenomics, Boehringer Ingelheim, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, Merck, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed Pharmaceuticals, Pfizer, Sanofi, Seattle Genetics, TG Therapeutics, and Xbiotech.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is emergence of targeted and combination therapies. Targeted and combination therapies are being increasingly developed for the treatment of cancers and inflammatory diseases. These therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse side effects than conventional non-targeted therapies.”

According to the report, one of the major drivers for this market is increase in demand for ADCs. Antibodies are increasingly becoming the preferred choice to treat diseases such as respiratory, oncology, and inflammatory diseases. Understanding diseases at a molecular level increases the development and use of antibodies. The use of ADCs, including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is growing. The increasing use of these antibodies in drug development increases revenue generation in the global next-generation biologics market, thereby contributing to the cancer mAbs market growth.

Further, the report states that one of the major factors hindering the growth of this market is complicated regulatory framework. Gaining regulatory approval is often difficult, unpredictable, and subjective. Biologics products must undergo a broad range of stringent regulations before approval and commercialization. Currently, the US FDA has approved very few products for stem cell therapy. However, there are several transplant centers running in the region that uses unapproved cell therapies.

Companies Mentioned

F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, Takeda Pharmaceuticals, AbbVie, ADC Therapeutics, Agensys, Argos Therapeutics, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, BioGenomics, Boehringer Ingelheim, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, Merck, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed Pharmaceuticals, Pfizer, Sanofi, Seattle Genetics, TG Therapeutics, and Xbiotech.

  • Executive summary
  • Scope of the report
    • Market overview
    • Assumptions
    • Top-vendor offerings
      • Table Offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key buying criteria for cancer mAbs 2016
      • Table Impact of key customer segments on the market 2016
  • mAbs: Overview
    • Evolution of mAb therapeutics
      • Table Comparison of small molecule and mAbs
      • Table Preparation of mAbs
      • Table Types of mAbs
    • Conjugated cancer therapies using mAbs
      • Table Targeted mechanisms of cancer mAbs
  • Timeline of mAbs for cancer
    • Table Timeline of mAbs for cancer
  • Pipeline portfolio
    • Table Global cancer mAbs market: Share of pipeline molecules
    • List of Phase III pipeline molecules
      • Table Global cancer mAbs market: Phase III pipeline molecules
    • List of Phase II pipeline molecules
      • Table Global cancer mAbs market: Phase II pipeline molecules
    • List of Phase I pipeline molecules
      • Table Global cancer mAbs market: Phase I pipeline molecules
  • Market landscape
    • Market overview
      • Table Overview of global cancer mAb market 2016-2021
      • Table Global cancer mAbs market snapshot: Developed and emerging markets 2016
      • Table Global cancer mAbs market 2016-2021 ($ billions)
      • Table A few of patient assistance programs offered by various drugs
      • Table Few awareness programs for various cancers
      • Table Patent expiries of top-selling mAbs by 2021 in US
      • Table Patent expiries of top selling mAbs by 2021 in Europe
      • Table Annual treatment cost per patient for various oncology drugs 2015
      • Table Analysis of global cancer mAbs market by type of application
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of mAbs
    • Table Market share of global cancer mAbs market by type of mAbs:
    • Naked mAbs
      • Table US FDA- and EU-approved naked cancer mAbs
    • Conjugated mAbs
      • Table Currently available conjugated mAbs
  • Market segmentation by MOA
    • Table Market segmentation by MOA
    • Immune system suppressors
    • Kill or inhibit malignant cells
    • Angiogenesis inhibitors
    • Radiation therapy to cancer cells
    • Delivering chemotherapy to cancer cells
  • Geographical segmentation
    • Table Global cancer mAbs market revenue by geography 2016-2021 ($ billions)
    • Cancer mAbs market in Americas
      • Table Overview of cancer mAbs market in Americas
      • Table Cancer mAbs market in Americas 2016-2021 ($ billions)
      • Table Cancer mAb market in Americas: Opportunity analysis
      • Table Cancer mAbs market in Americas by country 2015
      • Table Cancer mAbs market in US 2016-2021 ($ billions)
    • Cancer mAbs market in EMEA
      • Table Overview of cancer mAbs market in EMEA
      • Table Cancer mAbs market in EMEA 2016-2021 ($ billions)
      • Table Cancer mAbs market in EMEA by country 2016
      • Table Cancer mAb market in EMEA: Opportunity analysis
    • Cancer mAbs market in APAC
      • Table Overview of cancer mAbs market in APAC
      • Table Cancer mAbs market in APAC 2016-2020 ($ billions)
      • Table Cancer mAb market in APAC: Opportunity analysis
  • Market drivers
    • Increase in demand for ADCs
      • Table Timeline of ADCs
      • Table ADC molecules under clinical trials
    • Special regulatory drug designations
      • Table Special regulatory designations approved by US FDA
      • Table Special regulatory designations approved by EU
    • Advanced technological innovations
      • Table Advances in ADCs technology
      • Table Advances in engineered and bispecific antibodies technology
    • Increase in industry-academia collaborations
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Complicated regulatory framework
    • Absence of adequate diagnosis and screening procedures
    • High manufacturing costs coupled with stringent regulations
    • Threat from chemotherapy and off-label drugs
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Emergence of targeted and combination therapies
      • Table Expected combination regimen launches in oncology
    • Joint ventures and partnerships for R&D
    • Advent of biosimilars expected to improve the treatment rates
  • Vendor landscape
    • Competitive scenario
      • Table Market share analysis 2016
      • Table YoY sales comparison of top cancer mAbs 2013-2015 ($ billions)
      • Table Competitive assessment of vendors
      • Table Key vendors: Geographical presence 2015
    • Key news
    • Other prominent vendors
  • Key vendor analysis
    • Amgen
      • Table Amgen: Key highlights
      • Table Amgen: Strength assessment
      • Table Amgen: Strategy assessment
      • Table Amgen: Opportunity assessment
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb: Key highlights
      • Table Bristol-Myers Squibb: Strength assessment
      • Table Bristol-Myers Squibb: Strategy assessment
      • Table Bristol-Myers Squibb: Opportunity assessment
    • F. Hoffmann-La Roche
      • Table Hoffmann-La Roche: Key highlights
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • Takeda Pharmaceuticals
      • Table Takeda Pharmaceuticals: Highlights
      • Table Takeda Pharmaceuticals: Strength assessment
      • Table Takeda Pharmaceuticals: Strategy assessment
      • Table Takeda Pharmaceuticals: Opportunity assessment
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report